Innate Pharma : FDA Grants Breakthrough Therapy Designation To Lacutamab For R/R Sezary Syndrome
(RTTNews) - Innate Pharma SA (IPHA) announced Monday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory Sezary Syndr
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief